| Type | 3-month Bubill | 9-month Bubill |
| Maturity | Feb 18, 2026 | Aug 19, 2026 |
| Allotted | E2.275bln | E1.722bln |
| Previous | E2.446bln | E1.78bln |
| Total sold | E3bln | E3bln |
| Target | E3bln | E3bln |
| Avg yield | 1.917% | 1.943% |
| Previous | 1.711% | 1.899% |
| Bid-to-cover | 1.43x | 2x |
| Previous | 1.95x | 1.8x |
| Bid-to-offer | 1.08x | 1.15x |
| Previous | 1.19x | 1.07x |
| Previous date | Oct 20, 2025 | Oct 20, 2025 |
Find more articles and bullets on these widgets:
US President Donald Trump is shortly due to deliver an announcement in the White House Oval Office. LIVESTREAM The announcement is expected to relate to drug pricing and could follow a similar template to a recent pledge from Pfizer.
No ratings actions for Belgium from Moody's, which is quoted in a press release on Bloomberg: "Moody's Ratings (Moody's) has completed a periodic review of the ratings of Belgium and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 October 2025 in which we reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), and recent developments. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future."
Below is the week’s data schedule, with MNI’s annotation of whether or not data will be postponed.
